descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2017 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Pediatric Infectious Disease Journal, volume 36, pages 349-350 (issn: 0891-3668,

Authors: Chemla, Cathy; Villena, Isabelle;

doi: 10.1097/inf.0000000000001435

pmid: 28187118

Sulfadoxine–Pyrimethamine Combination in Congenital Toxoplasmosis

- Summary
- Subjects
- Metrics

Abstract

International audience

Related Organizations

Centre Hospitalier Universitaire de Reims
France
Normandie Université
France
University of Reims Champagne-Ardenne
France

Keywords

Toxoplasmosis, Congenital, Antimalarials, Drug Combinations, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Pyrimethamine, environment/Health, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, Sulfadoxine, Humans, Drug Therapy, Combination

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average